Home Healthcare Pharmaceuticals Central Pain Syndrome Management Market

Central Pain Syndrome Management Market Size, Share & Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Analgesics, Antispastic Agents, Novel CNS Agents), By Application (Post-stroke Pain, Multiple Sclerosis, Traumatic Brain Injury, Parkinson’s Disease, Epilepsy, Other CNS Disorders), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 01, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Central Pain Syndrome Management Market, By Drug Class 2025-2034 (USD MILLION/ Units)
    1. Anticonvulsants
    2. Antidepressants
    3. Analgesics
    4. Antispastic Agents
    5. Novel CNS Agents
  2. Central Pain Syndrome Management Market, By Application 2025-2034 (USD MILLION/ Units)
    1. Post-stroke Pain
    2. Multiple Sclerosis
    3. Traumatic Brain Injury
    4. Parkinson’s Disease
    5. Epilepsy
    6. Other CNS Disorders
  3. Central Pain Syndrome Management Market, By Distribution Channel 2025-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  4. Regional Central Pain Syndrome Management Market
    1. North America
      1. North America Central Pain Syndrome Management Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
      2. North America Central Pain Syndrome Management Market By Application 2025-2034 (USD MILLION/ Units)
        1. Post-stroke Pain
        2. Multiple Sclerosis
        3. Traumatic Brain Injury
        4. Parkinson’s Disease
        5. Epilepsy
        6. Other CNS Disorders
      3. North America Central Pain Syndrome Management Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Canada
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    2. Europe
      1. Europe Central Pain Syndrome Management Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
      2. Europe Central Pain Syndrome Management Market By Application 2025-2034 (USD MILLION/ Units)
        1. Post-stroke Pain
        2. Multiple Sclerosis
        3. Traumatic Brain Injury
        4. Parkinson’s Disease
        5. Epilepsy
        6. Other CNS Disorders
      3. Europe Central Pain Syndrome Management Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Germany
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. France
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Spain
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Italy
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Russia
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Nordic
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Benelux
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      12. Rest of Europe
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    3. APAC
      1. APAC Central Pain Syndrome Management Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
      2. APAC Central Pain Syndrome Management Market By Application 2025-2034 (USD MILLION/ Units)
        1. Post-stroke Pain
        2. Multiple Sclerosis
        3. Traumatic Brain Injury
        4. Parkinson’s Disease
        5. Epilepsy
        6. Other CNS Disorders
      3. APAC Central Pain Syndrome Management Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Korea
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Japan
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. India
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Australia
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Taiwan
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. South East Asia
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Rest of Asia-Pacific
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Central Pain Syndrome Management Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
      2. Middle East and Africa Central Pain Syndrome Management Market By Application 2025-2034 (USD MILLION/ Units)
        1. Post-stroke Pain
        2. Multiple Sclerosis
        3. Traumatic Brain Injury
        4. Parkinson’s Disease
        5. Epilepsy
        6. Other CNS Disorders
      3. Middle East and Africa Central Pain Syndrome Management Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Turkey
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Saudi Arabia
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. South Africa
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Egypt
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Nigeria
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Rest of MEA
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    5. LATAM
      1. LATAM Central Pain Syndrome Management Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
      2. LATAM Central Pain Syndrome Management Market By Application 2025-2034 (USD MILLION/ Units)
        1. Post-stroke Pain
        2. Multiple Sclerosis
        3. Traumatic Brain Injury
        4. Parkinson’s Disease
        5. Epilepsy
        6. Other CNS Disorders
      3. LATAM Central Pain Syndrome Management Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Mexico
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Argentina
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Chile
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Colombia
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Rest of LATAM
        1. Anticonvulsants
        2. Antidepressants
        3. Analgesics
        4. Antispastic Agents
        5. Novel CNS Agents
        6. Post-stroke Pain
        7. Multiple Sclerosis
        8. Traumatic Brain Injury
        9. Parkinson’s Disease
        10. Epilepsy
        11. Other CNS Disorders
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.